Patient P-01446
Synthetic patientNBL-101 · Day 119 · 55–64 · F · baseline S03Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Stable
Discontinuation risk
32%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S03
- Day 53 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 53.
Primary contributors, last 14 days
- GI instability+6
- Inflammatory activity+5
- Nutritional resilience+3
- Treatment adherence-3
- Toxicity+3
What helped?
No interventions yet.
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
46%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 71% showed improvement
- median effect visible after 5 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion39.7/100
worsening · +1.5 vs previous 14 d
Toxicity
Blood14.4/100
improving · -3.0 vs previous 14 d
Sleep quality
Wearable52.5/100
improving · +3.4 vs previous 14 d
Energy level
Daily log4.9/10
stable · +0.2 vs previous 14 d
Stress level
Daily log5.3/10
improving · -0.4 vs previous 14 d
Steps
Wearable8,638
stable · +94 vs previous 14 d
Adherence
Companion89.2 %
stable · +0.9 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 49 from the failing basin, 38 from restoration.
Would help
- DT-01 Dosing / Timing Recommendation71% improved among 7 similar · onset 5 d · confidence 48%
Would not help
- Nothing clearly counter-productive in the record.
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Spicy / capsaicin-1.9no signal · 40%
- Dietary fat load+1.2no signal · 28%
- Simple carbohydrates+0.9no signal · 23%
- Insoluble fibre+0.7no signal · 15%
- Alcohol-0.6no signal · 15%
- Histamine load+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 40
- WearableHRV 32 ms, trending down
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3.6 · butyrate capacity 52/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 36 ms
- Sleep
- 7.6 h
- Steps
- 9,111
- Resting HR
- 58 bpm
Daily log: GI score 40, nutritional resilience 58, adherence 89.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01571 | 46% | S13 | SC-12 | improved | 57 |
| P-01430 | 44% | S05 | CR-01 | improved | 54 |
| P-01342 | 42% | S11 | DT-01 | improved | 48 |
| P-01804 | 42% | S19 | AD-05 | improved | 61 |
| P-01346 | 36% | S12 | DT-01 | improved | 52 |
| P-01593 | 36% | S10 | HY-01 | improved | 56 |
| P-01752 | 36% | S20 | DT-01 | improved | 50 |
| P-01861 | 34% | S12 | HY-01 | improved | 47 |
| P-01321 | 32% | S12 | GI-04 | improved | 53 |
| P-01374 | 32% | S08 | HY-01 | improved | 49 |
| P-01724 | 32% | S10 | DT-01 | improved | 63 |
| P-01383 | 31% | S14 | NP-02 | improved | 40 |